.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Two-year results from the phase 3 YOSEMITE and RHINE trials evaluated faricimab delivered through a personalized treat-and-extend approach in diabetic macular edema (DME). Visual acuity gains were maintained through year two and were noninferior to aflibercept dosed every eight weeks. An important feature was durability: many patients receiving faricimab in the treat-and-extend arms could be extended to 12- or 16-week intervals, reducing the number of injections required over the study period. Anatomic improvements were also sustained, with reductions in central subfield thickness and improved fluid control. For retina specialists, the study reinforces the value of treatment interval personalization. Rather than treating every patient at a fixed frequency, clinicians can adjust dosing according to visual and anatomic response while preserving meaningful gains. This approach may reduce treatment burden for patients who respond well, especially in chronic diseases such as DME where repeated intravitreal injections can become a major barrier to long-term adherence. The study also supports the concept that durability is now a central efficacy endpoint alongside visual acuity and OCT anatomy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Two-year results from the phase 3 YOSEMITE and RHINE trials evaluated faricimab delivered through a personalized treat-and-extend approach in diabetic macular edema (DME). Visual acuity gains were maintained through year two and were noninferior to aflibercept dosed every eight weeks. An important feature was durability: many patients receiving faricimab in the treat-and-extend arms could be extended to 12- or 16-week intervals, reducing the number of injections required over the study period. Anatomic improvements were also sustained, with reductions in central subfield thickness and improved fluid control. For retina specialists, the study reinforces the value of treatment interval personalization. Rather than treating every patient at a fixed frequency, clinicians can adjust dosing according to visual and anatomic response while preserving meaningful gains. This approach may reduce treatment burden for patients who respond well, especially in chronic diseases such as DME where repeated intravitreal injections can become a major barrier to long-term adherence. The study also supports the concept that durability is now a central efficacy endpoint alongside visual acuity and OCT anatomy.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
5 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
